*ST长药
(300391)
| 流通市值：16.57亿 | | | 总市值：16.57亿 |
| 流通股本：3.50亿 | | | 总股本：3.50亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 9,012,776.1 | 8,296,536.14 | 6,736,442.47 | 10,060,539.75 |
| 应收票据及应收账款 | 1,023,063,349.86 | 980,553,203.98 | 1,521,898,918.72 | 1,520,312,110.34 |
| 其中：应收票据 | - | 636,228.97 | - | - |
| 应收账款 | 1,023,063,349.86 | 979,916,975.01 | 1,521,898,918.72 | 1,520,312,110.34 |
| 应收款项融资 | 96,575.7 | 222,168 | - | 95,000 |
| 预付款项 | 17,141,735.53 | 11,498,498.01 | 126,690,564 | 126,371,398.87 |
| 其他应收款合计 | 71,483,649.17 | 66,147,674.22 | 73,937,024.55 | 73,220,153.25 |
| 存货 | 46,773,287.62 | 42,450,996.74 | 45,420,832.36 | 54,152,171.68 |
| 合同资产 | 4,596,271.29 | 4,596,271.29 | 5,276,585 | 845,310 |
| 其他流动资产 | 12,462,190.12 | 15,592,070.73 | 44,074,543.65 | 50,405,888.8 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,184,629,835.39 | 1,129,357,419.11 | 1,824,034,910.75 | 1,835,462,572.69 |
| 非流动资产: | | | | |
| 固定资产 | 625,646,989.67 | 632,215,922.55 | 741,810,585.73 | 748,715,192.05 |
| 在建工程 | - | 0 | 196,079,457.12 | 189,248,247.61 |
| 生产性生物资产 | - | 0 | - | - |
| 使用权资产 | 1,572,377.07 | 2,513,202.55 | 6,096,289.4 | 6,449,351.66 |
| 无形资产 | 76,911,530.56 | 77,506,356.64 | 97,196,130.68 | 97,829,636.11 |
| 商誉 | 16,368,263.14 | 16,368,263.14 | 208,626,653.9 | 208,626,653.9 |
| 长期待摊费用 | 137,367,727.53 | 137,723,358.13 | - | - |
| 递延所得税资产 | - | 0 | 16,466,500.21 | 16,466,500.21 |
| 其他非流动资产 | - | 33,120 | 813,500 | 5,011,550 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 857,866,887.97 | 866,360,223.01 | 1,267,089,117.04 | 1,272,347,131.54 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,042,496,723.36 | 1,995,717,642.12 | 3,091,124,027.79 | 3,107,809,704.23 |
| 流动负债: | | | | |
| 短期借款 | 208,483,849.3 | 208,483,849.3 | 199,983,957.28 | 219,723,957.28 |
| 应付票据及应付账款 | 243,140,887.95 | 223,268,376.43 | 326,370,055.38 | 326,968,840.76 |
| 其中：应付票据 | 834,496.91 | 861,909.51 | 432,610.6 | 1,492,579.6 |
| 应付账款 | 242,306,391.04 | 222,406,466.92 | 325,937,444.78 | 325,476,261.16 |
| 合同负债 | 20,363,661.06 | 23,088,272.6 | 14,435,132.69 | 13,740,047.15 |
| 应付职工薪酬 | 27,656,623.7 | 28,779,268.39 | 25,905,222.42 | 26,596,796.64 |
| 应交税费 | 124,469,271.54 | 123,884,087.07 | 124,788,023.67 | 124,962,058.84 |
| 其他应付款合计 | 1,324,188,274.25 | 1,219,957,419.48 | 1,032,401,992.7 | 961,978,704.38 |
| 其中:应付利息 | 12,738,377.66 | 7,824,242.86 | 26,018,119.6 | 23,889,067.47 |
| 一年内到期的非流动负债 | 95,825,669.69 | 95,089,653.72 | 106,957,395.84 | 106,956,270.75 |
| 其他流动负债 | 1,064,562.89 | 2,093,902.42 | 538,078.48 | 538,078.48 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 2,045,192,800.38 | 1,924,644,829.41 | 1,831,379,858.46 | 1,781,464,754.28 |
| 非流动负债: | | | | |
| 长期借款 | 444,399,000 | 444,399,000 | 480,899,000 | 510,899,000 |
| 租赁负债 | 1,399,069.21 | 1,387,586.84 | 5,923,596.53 | 5,957,344.53 |
| 预计负债 | 45,808,696.12 | 30,084,303.04 | 12,954,720.81 | 11,039,939.98 |
| 递延收益 | 14,833,066.4 | 14,914,866.41 | 14,996,666.42 | 15,078,466.43 |
| 递延所得税负债 | 1,595,995.97 | 1,595,995.97 | 7,103,618.38 | 7,103,618.39 |
| 其他非流动负债 | 19,672.57 | 46,082.76 | 650,313.53 | 650,313.53 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 508,055,500.27 | 492,427,835.02 | 522,527,915.67 | 550,728,682.86 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 2,553,248,300.65 | 2,417,072,664.43 | 2,353,907,774.13 | 2,332,193,437.14 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 350,336,112 | 350,336,112 | 350,336,112 | 350,336,112 |
| 资本公积 | 788,172,222.03 | 788,172,222.03 | 788,172,222.03 | 788,172,222.03 |
| 盈余公积 | 18,358,424.24 | 18,358,424.24 | 18,358,424.24 | 18,358,424.24 |
| 未分配利润 | -1,650,519,734.61 | -1,589,707,417.48 | -1,142,716,415.97 | -1,114,318,748.05 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | -493,652,976.34 | -432,840,659.21 | 14,150,342.3 | 42,548,010.22 |
| 少数股东权益 | -17,098,600.95 | 11,485,636.9 | 723,065,911.36 | 733,068,256.87 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | -510,751,577.29 | -421,355,022.31 | 737,216,253.66 | 775,616,267.09 |
| 负债和股东权益合计 | 2,042,496,723.36 | 1,995,717,642.12 | 3,091,124,027.79 | 3,107,809,704.23 |
| 公告日期 | 2025-04-28 | 2025-04-21 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |